Ofev (nintedanib) is safe and effective for adults with idiopathic pulmonary fibrosis (IPF) with poorer lung function, a small real-world analysis has found. Age and lung function predicted the therapy’s efficacy in this group of patients. …
Ofev Effective in IPF Patients With Poor Lung Function, Real-world Study Finds
Research investigating the role of immune cells in triggering lung and heart rejection following transplant will be supported by $10 million in grants from the National Institutes of Health (NIH). The grants, awarded to scientists at Washington University School of Medicine in St. Louis, will support research that aims…
Same But Different, a U.K. nonprofit that uses the arts to bring communities together, is holding a calendar photography competition to raise awareness for rare diseases. Under the theme “A Glimmer of Hope,” the competition is a means to “visually express the hope that exists for people affected by…
As we launch into Pulmonary Fibrosis Awareness Month this September, I personally believe there’s a lot that can be done to educate others and to raise the profile of this cruel and life-threatening lung disease. I look forward to sharing in an upcoming column more tangible ideas about how…
Japanese people diagnosed with both pulmonary fibrosis (PF) and emphysema appear to carry a single genetic mutation that contributes to the development of both conditions, a study reports. This mutation was linked to lower levels of the anti-inflammatory…
In the U.S., idiopathic pulmonary fibrosis (IPF) mortality rates decreased from 2004 to 2017, a new study shows. The data suggests the decline might be partly explained by a decline in smoking, but further research is needed to better understand the factors contributing to this trend. The study, “Mortality Trends…
Galecto‘s investigational compound GB0139, now in an enrolling clinical trial, has been designated an orphan drug by the U.S. Food and Drug Administration and the European Medicines Agency (EMA) as a potential treatment of idiopathic pulmonary fibrosis (IPF). GB0139 (formerly TD139) is an inhaled small molecule inhibitor of…
Receiving a pulmonary fibrosis diagnosis is a life-changing event. Accepting this new reality may initially seem impossible. There are so many new things to consider that never were on the radar before they suddenly became important. In addition to finding your footing in the present, you must…
AbbVie will assume development of Morphic Therapeutic‘s alpha v beta 6 (αvβ6) integrin inhibitors as potential treatments for idiopathic pulmonary fibrosis (IPF) and other fibrotic diseases, exercising a licensing option under an earlier research partnership between the companies. Integrins control a wide variety of cellular processes, including…
At some point in everyone’s lives, we feel overwhelmed by the pressure to perform, whether it’s getting good grades at school, excelling at playing an instrument, or receiving a promotion at work. Many of these are normal pressures one expects throughout their lives. However, patients with idiopathic pulmonary fibrosis (IPF),…
